Alembic Pharmaceuticals Limited Stock Price Today (NSE: APLLTD)
Fundamental Score
Alembic Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Alembic Pharmaceuticals Limited share price today is ₹825.30, up +0.07% on NSE/BSE as of 16 September 2026. Alembic Pharmaceuticals Limited (APLLTD) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹16.22K (Cr). The 52-week high for APLLTD share price is ₹998.00 and the 52-week low is ₹635.80. At a P/E ratio of 23.40x, APLLTD is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 12.35% and a debt-to-equity ratio of 0.24.
Alembic Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Alembic Pharmaceuticals Limited share price chart: -2.75% return over the past month. 52-week high ₹998.00, 52-week low ₹635.80.
Alembic Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹817.30 | ₹839.95 | ₹813.20 | ₹825.30 | 1.36L (Cr) | |
| ₹811.00 | ₹839.35 | ₹810.20 | ₹824.75 | 1.65L (Cr) | |
| ₹806.00 | ₹822.00 | ₹799.20 | ₹810.95 | 1.19L (Cr) | |
| ₹818.55 | ₹836.50 | ₹813.80 | ₹816.40 | 1.20L (Cr) | |
| ₹804.50 | ₹821.50 | ₹799.10 | ₹817.40 | 86.24K (Cr) | |
| ₹802.00 | ₹810.95 | ₹792.60 | ₹808.50 | 2.00L (Cr) | |
| ₹808.00 | ₹828.10 | ₹797.40 | ₹799.55 | 1.71L (Cr) | |
| ₹805.00 | ₹811.75 | ₹792.60 | ₹808.20 | 1.74L (Cr) | |
| ₹833.50 | ₹833.50 | ₹801.10 | ₹803.65 | 1.64L (Cr) | |
| ₹845.00 | ₹859.00 | ₹823.25 | ₹826.90 | 1.73L (Cr) |
Alembic Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹835.00 | ₹859.00 | ₹792.60 | ₹825.30 | -1.16% | |
| ₹797.05 | ₹855.90 | ₹792.55 | ₹834.90 | +4.75% | |
| ₹843.20 | ₹855.40 | ₹787.40 | ₹797.05 | -5.47% | |
| ₹736.00 | ₹832.05 | ₹706.90 | ₹822.75 | +11.79% | |
| ₹759.95 | ₹809.00 | ₹710.70 | ₹736.10 | -3.14% | |
| ₹668.95 | ₹797.00 | ₹644.50 | ₹755.00 | +12.86% | |
| ₹700.00 | ₹725.35 | ₹635.80 | ₹663.25 | -5.25% | |
| ₹779.00 | ₹827.45 | ₹705.00 | ₹711.20 | -8.70% | |
| ₹843.00 | ₹849.00 | ₹744.75 | ₹783.20 | -7.09% | |
| ₹909.40 | ₹920.00 | ₹834.95 | ₹846.15 | -6.96% | |
| ₹897.40 | ₹998.00 | ₹885.70 | ₹907.20 | +1.09% | |
| ₹901.35 | ₹952.20 | ₹890.50 | ₹897.40 | -0.44% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Alembic Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Alembic Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of APLLTD across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Operating Margins (15.24%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 23.40 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (25.66%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.24)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (8.41x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 1.69)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹755.44 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (69.74%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Weak Earnings Growth (-10.81% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-10.65% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Alembic Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Alembic Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Alembic Pharmaceuticals LimitedAlembic Pharmac...Selected✓ APLLTD • 533573 | 48.3/100 | ₹825.30₹825 | ₹16221.27₹16221.27 | 23.40Average 23.4 Average | 12.35%Average 12.35% Average | 13.66%Average 13.66% Average | 0.24Excellent 0.2 Excellent | -10.65%Poor -10.65% Poor | 6.37%Good 6.37% Good | 1.41% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Alembic Pharmaceuticals Limited PE Ratio History
Historical price-to-earnings ratio for APLLTD — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹29.68 | ₹846.15 | 28.5x |
| FY 2024 | ₹31.33 | ₹1066.25 | 34x |
| FY 2023 | ₹17.40 | ₹759.40 | 43.6x |
| FY 2022 | ₹26.50 | ₹572.90 | 21.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Alembic Pharmaceuticals Limited Dividend History
Annual cash dividends paid by APLLTD — dividend yield 1.41%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹216.22 Cr |
| FY 2024 | ₹157.25 Cr |
| FY 2023 | ₹196.56 Cr |
| FY 2022 | ₹275.19 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Alembic Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for APLLTD — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
25.66%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
12.11%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
6.37%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-10.65%
Compounded annual net profit growth over 5 years
Alembic Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for APLLTD — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Alembic Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Alembic Pharmaceuticals Limited (APLLTD) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Alembic Pharmaceuticals Limited
About APLLTD (Alembic Pharmaceuticals Limited)
Alembic Pharmaceuticals Ltd is a dynamic and multifaceted player in the global pharmaceutical arena, deeply rooted in a rich legacy of scientific innovation and unwavering commitme...nt to healthcare. The company operates with a broad spectrum of capabilities, spanning the entire pharmaceutical value chain, from meticulous research and development to advanced manufacturing processes and strategic marketing initiatives. Their dedication to quality and precision ensures that every product meets the highest international standards, delivering safe and effective treatments to patients across diverse therapeutic areas. Alembic Pharmaceuticals Ltd embodies a relentless pursuit of excellence, constantly pushing the boundaries of pharmaceutical science to address unmet medical needs and improve patient outcomes. Driven by a patient-centric philosophy, Alembic Pharmaceuticals Ltd crafts a diverse portfolio of pharmaceutical solutions targeting a wide range of prevalent and emerging health challenges. This includes developing innovative formulations and generics across various therapeutic specialties, such as cardiovascular health, musculoskeletal disorders, metabolic diseases, and ophthalmic conditions. The company's relentless focus on research and development allows them to stay at the forefront of pharmaceutical advancements, continuously introducing new and improved treatment options to healthcare providers and patients alike. Furthermore, Alembic Pharmaceuticals Ltd is committed to fostering strategic partnerships and collaborations, expanding their reach and impact within the global healthcare landscape. Alembic Pharmaceuticals Ltd distinguishes itself through its unwavering dedication to ethical business practices, environmental sustainability, and social responsibility. They operate with transparency and integrity in all aspects of their business, ensuring compliance with the most stringent regulatory standards and fostering trust with stakeholders. The company also recognizes the importance of environmental stewardship and actively implements sustainable practices to minimize its environmental footprint. In addition, Alembic Pharmaceuticals Ltd is deeply committed to giving back to the community through various social initiatives, supporting education, healthcare, and other programs that improve the quality of life for individuals and families in need.
Company Details
Key Leadership
APLLTD Share Price: Frequently Asked Questions
What is the current share price of Alembic Pharmaceuticals Limited?
Alembic Pharmaceuticals Limited (APLLTD) trades at ₹825.30 on NSE and BSE. Market cap ₹16.22K (Cr). Educational data only.
What is the P/E ratio of Alembic Pharmaceuticals Limited?
Alembic Pharmaceuticals Limited has a P/E of 23.40x vs industry average 34.89x.
What is the Bull Run score for Alembic Pharmaceuticals Limited?
Alembic Pharmaceuticals Limited has a Bull Run score of 48.3/100 based on 25+ financial parameters.
Does Alembic Pharmaceuticals Limited pay dividends?
Alembic Pharmaceuticals Limited has a dividend yield of 1.41%. Past dividends don't guarantee future payments.
What is the ROE of Alembic Pharmaceuticals Limited?
Alembic Pharmaceuticals Limited has ROE of 12.35%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Alembic Pharmaceuticals Limited?
Alembic Pharmaceuticals Limited has debt-to-equity of 0.24.
Is Alembic Pharmaceuticals Limited a good investment?
Bull Run gives Alembic Pharmaceuticals Limited a score of 48.3/100. This is not investment advice — consult a SEBI-registered advisor.